Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy

Abstract

To derive a CT-based scoring system incorporating arterial involvement and resectability status to predict R0 resection in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing neoadjuvant chemoradiation therapy (CRT). This retrospective study included 112 patients with PDAC who underwent dynamic contrast-enhanced CT before and after neoadjuvant CRT. A 5-point score was used to determine arterial involvement (A score; 1\u2009=\u2009no involvement, 2\u2009=\u2009haziness, 3\u2009=\u2009abutment, 4\u2009=\u2009encasement, 5\u2009=\u2009deformity) and 4-point score evaluating resectability status (R score; 1\u2009=\u2009resectable, 2\u2009=\u2009borderline resectable [BR] with venous involvement, 3\u2009=\u2009BR with arterial involvement, 4\u2009=\u2009locally advanced [LA]). A score before and after CRT were summed with R score before and after CRT to compute the AR score (ARtotal). The associations between ARtotal, R0 resection, overall survival (OS), and disease-free survival (DFS) were assessed. The ARtotal was associated with R0 resection (p\u2009<\u2009.001) and showed area under the ROC curve of 0.79 for differentiating R0 and R1 resections. Median OS was significantly lower for patients with ARtotal >\u20099 (median: 35.2 months) compared to patients with ARtotal\u2009≤\u20099 (median: not estimable) (p\u2009<\u2009.001). Similar results were observed for DFS (median, 16.8 months in\u2009>\u20099 vs median, not estimable in\u2009≤\u20099; p\u2009<\u2009.001). A composite score which incorporates degree of arterial involvement and resectability status before and after neoadjuvant CRT is associated with R0 resection and discriminates between R0 and R1 resections in PDAC. • A scoring system incorporating arterial involvement and resectability status was associated with R0 resection. • ARtotal >\u2009 9 could predict patients overall and disease-free survival.